News Search Results

Displaying Results 1326-1350 of 4502 "biotechnology"

Sep 18, 2025, 10:00 ET Roche achieves first CLIA 'Moderate Complexity' categorization for Ionify® 25-Hydroxy Vitamin D total test

Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics

More news about: Roche Diagnostics


Sep 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCY

[Click here for information about joining the class action] Unicycive is a clinical-stage biotechnology company that identifies, develops, and commercializes therapies to address unmet medical needs in the U.S.  The Company is developing, among other

More news about: Pomerantz LLP


Sep 18, 2025, 09:20 ET AIChE Awards Its 2025 Langer Prize to Mark Blenner of the University of Delaware

regulation to catch up; therefore, innovations must deliver significant value to early adopters and have the potential to scale to larger markets. Biotechnology, including microbes and enzymes, has the potential to efficiently process mixed, uncleaned plastic waste and be deployed in decentralized

More news about: American Institute Of Chemical Engineers


Sep 18, 2025, 09:10 ET Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

27% growth rate[4]. Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic pivot into the high-growth longevity biotechnology sector through a transformative joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.), establishing

More news about: USA News Group


Sep 18, 2025, 09:00 ET Yoé Skincare, Known for Outperforming Beyond the Surface, Launches at Bloomingdale's

autoimmune-related skin sensitivity. When existing products failed to deliver results without irritation, Guo set out to create formulas rooted in biotechnology, skincare that delivers visible transformation by working beyond the surface. Yoé's hero products, the Ympossible Cream

More news about: Yoé & Co


Sep 18, 2025, 08:45 ET Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

between 2025 and 2034. The growth of the cell therapy market is driven by the increase in investments in research and development and advancements in biotechnology. Healthcare companies active in the markets this week include: Avant Technologies Inc. (OTCQB: AVAI), Tempus AI, Inc. (NASDAQ: TEM),

More news about: MarketNewsUpdates


Sep 18, 2025, 08:45 ET Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

the skin, leading to an immune reaction and inflammation. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.

More news about: Nektar Therapeutics


Sep 18, 2025, 08:30 ET Avant Technologies and Austrianova Sign Joint Venture, Licensing Agreement to Advance Klotho-Based Therapies

Nevada-based corporation, and Austrianova (SGAustria Pte. Ltd.), a Singapore-based biotechnology leader, today announced the formation of a Joint Venture and License Agreement to establish Klothonova, Inc., a new Nevada

More news about: Avant Technologies Inc.


Sep 18, 2025, 08:30 ET Advancing Small Molecule Drug Discovery - New Developments in DEL Technology, Upcoming Webinar Hosted by Xtalks

the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access

More news about: Xtalks


Sep 18, 2025, 07:00 ET K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annual International Myeloma Society Meeting

Sept. 18, 2025 /PRNewswire/ -- K36 Therapeutics, Inc. ("K36"), a privately held clinical-stage biotechnology company developing novel, targeted therapies for cancers with unmet medical need, today announced the presentation of two posters at the 22nd

More news about: K36 Therapeutics


Sep 18, 2025, 07:00 ET Marengo Therapeutics Advances STARt-002 Clinical Trial into Phase 2 Cohort Expansion Evaluating Invikafusp Alfa with TROP2-directed ADC TRODELVY® in Metastatic Breast Cancer

Sept. 18, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision immunotherapy in oncology, inflammation and immunology (I&I), today announced the completion

More news about: Marengo Therapeutics


Sep 18, 2025, 06:55 ET Heat Transfer Fluids Market worth $6.3 billion by 2030 - Exclusive Report by MarketsandMarkets™

temperature-sensitive products, has significantly contributed to this segment's expansion. Additionally, the adoption of advanced technologies in biotechnology, semiconductor manufacturing, and electronics testing has increased the need for HTFs that perform efficiently without crystallization or loss of

More news about: MarketsandMarkets


Sep 18, 2025, 06:00 ET PlantArcBio Secures U.S. and South Korea Patents for DIPPER™ Platform, Advancing Gene-Editing Optimization in Crops

The DIPPER™ platform represents a significant advancement in plant biotechnology, enabling researchers and breeders to enhance the efficiency and precision of processes using gene-editing tools such as CRISPR to improve crop

More news about: PlantArcBio


Sep 17, 2025, 21:00 ET Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

myasthenia gravis (gMG). About Vor Bio Vor Bio is a clinical-stage biotechnology company committed to the treatment of autoimmune diseases. The company focuses on rapidly advancing the Phase III clinical development and commercialization

More news about: RemeGen Co., Ltd


Sep 17, 2025, 19:30 ET Ascletis Presented Phase III Study Results of First-in-Class FASN Inhibitor Denifanstat (ASC40) for Acne Treatment in the Late Breaking News Sessions of the European Academy of Dermatology and Venereology (EADV) Congress 2025

rights in Greater China. About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.

More news about: Ascletis Pharma Inc.


Sep 17, 2025, 18:01 ET Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes

life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:

More news about: Eli Lilly and Company


Sep 17, 2025, 17:09 ET MagicRNA's First-in-Human Clinical Data Demonstrating Feasibility of In Vivo CAR T Therapy in Systemic Lupus Erythematosus Published in The New England Journal of Medicine.

China, Sept. 17, 2025 /PRNewswire/ -- MagicRNA, a clinical-stage biotechnology company pioneering in vivo CAR T-cell therapies, today announced the publication of the world's first clinical data of an mRNA-lipid nanoparticle

More news about: Shenzhen MagicRNA Biotech Co., Ltd.


Sep 17, 2025, 14:47 ET Thryv Therapeutics Announces FDA IND Clearance of THRV-1268 for Long QT Syndrome

MONTREAL, Sept. 17, 2025 /PRNewswire/ - Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for cardiovascular diseases, today announced that the U.S. Food

More news about: Thryv Therapeutics Inc.


Sep 17, 2025, 14:00 ET Bio Protocol Raises $6.9M to Launch AI-Native Decentralized Science Platform for Biotech Funding & Drug Discovery

2025 /PRNewswire/ -- Bio Protocol, the decentralized science (DeSci) platform building AI-native infrastructure for biotechnology, today announced it has raised $6.9 million in a funding round anchored by Maelstrom Fund, with participation from

More news about: BIO.XYZ


Sep 17, 2025, 12:00 ET Terra Oleo Emerges from Stealth with US$3.1M in Funding and Breakthrough Energy Fellow Selection to Reinvent Fats and Oils

Sept. 17, 2025 /PRNewswire/ -- Terra Oleo, a Singapore-based biotechnology company, today announced its emergence from stealth with US$3.1 million in funding from a group of investors, and

More news about: Terra Oleo


Sep 17, 2025, 11:51 ET Aker-Nscale JV signs Multi-Billion Dollar AI infrastructure agreement with Microsoft

Norway. Founded in 1841, Aker builds and develops leading companies across energy, industrial software, renewables, and marine biotechnology. As the largest shareholder in several listed and privately held companies, Aker combines deep industrial expertise, financial strength, and capital

More news about: Aker ASA


Sep 17, 2025, 11:31 ET Flagship Pioneering Appoints Mary Beth Harler President of Pioneering Medicines

in-house drug discovery and development unit. Dr. Harler comes to Flagship with more than two decades of senior leadership experience across the biotechnology and global pharmaceutical industries, spanning clinical development, organizational building, and corporate strategy.

More news about: Flagship Pioneering


Sep 17, 2025, 10:50 ET E-Cigarette Market Is Projected to Reach US$ 52.13 Billion By 2031 With A CAGR Of 10.8% |The Insight Partners

syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact

More news about: The Insight Partners


Sep 17, 2025, 10:40 ET Digital Health Market Is Projected to Reach US$ 1921.38 Billion By 2031 With CAGR Of 25.7% | The Insight Partners

syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact

More news about: The Insight Partners


Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.